Stoke Therapeutics (NASDAQ:STOK) Insider Sells $60,517.54 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Jason Hoitt sold 1,931 shares of Stoke Therapeutics stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total value of $60,517.54. Following the completion of the transaction, the insider owned 10,276 shares in the company, valued at approximately $322,049.84. This represents a 15.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Jason Hoitt also recently made the following trade(s):

• On Tuesday, March 17th, Jason Hoitt sold 1,781 shares of Stoke Therapeutics stock. The shares were sold at an average price of $33.01, for a total value of $58,790.81.

Stoke Therapeutics Price Performance

Shares of STOK stock opened at $33.51 on Friday. The business has a 50-day moving average of $32.61 and a 200 day moving average of $30.09. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $40.22. The stock has a market capitalization of $1.98 billion, a PE ratio of 50.01 and a beta of 1.07.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on STOK. Chardan Capital restated a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday. Loop Capital set a $35.00 price target on shares of Stoke Therapeutics in a report on Monday, January 5th. Wedbush raised their price target on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a report on Tuesday, March 17th. Guggenheim began coverage on shares of Stoke Therapeutics in a research report on Thursday, February 5th. They issued a “buy” rating and a $60.00 price objective on the stock. Finally, UBS Group set a $50.00 price objective on shares of Stoke Therapeutics in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $41.83.

Stoke Therapeutics News Roundup

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Canaccord raised its price target sharply to $60 and assigned a Buy, giving STOK a meaningful upside projection versus recent levels — a clear catalyst for buying interest. Canaccord raises STOK price target to $60 (Benzinga)
• Positive Sentiment: Other analysts reiterated/raised Buy views and targets (BTIG reaffirmed Buy with a $39 target; Wedbush pushed its target to $38; Needham published a bullish outlook), adding breadth to the bullish narrative and likely attracting momentum and institutional buyers. BTIG reaffirmation (Benzinga) Wedbush boosts price target to $38 (AmericanBankingNews) Needham bullish outlook (AmericanBankingNews)
• Positive Sentiment: Coverage of Stoke’s STK‑001 program emphasizes potential beyond seizure reduction (aiming to restore developmental loss in Dravet syndrome), supporting longer‑term upside expectations if clinical data meet endpoints. FierceBiotech: Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces reviewed a recent sharp pullback and what triggered it—useful context for traders but not a new company catalyst. Kalkine: What triggered the sudden drop?
• Neutral Sentiment: Technical/volume note — today’s volume is well above average and the stock is trading above both its 50‑ and 200‑day SMAs, indicating higher investor interest; this can amplify moves in either direction.
• Negative Sentiment: Significant insider selling: multiple executives (including the CFO, general counsel and senior insiders such as Barry Ticho) disclosed sizable sales across March 17–19, which can weigh on sentiment and prompt investor caution despite analyst optimism. Representative SEC filings: SEC Form 4 (Jonathan Allan) SEC Form 4 (Barry Ticho)

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Principal Financial Group Inc. bought a new stake in Stoke Therapeutics in the third quarter valued at $1,062,000. Marshall Wace LLP raised its holdings in Stoke Therapeutics by 7.9% in the 2nd quarter. Marshall Wace LLP now owns 2,300,554 shares of the company’s stock worth $26,111,000 after purchasing an additional 168,771 shares in the last quarter. Penserra Capital Management LLC bought a new position in Stoke Therapeutics in the 3rd quarter worth $3,539,000. Franklin Resources Inc. lifted its position in shares of Stoke Therapeutics by 264.8% in the 2nd quarter. Franklin Resources Inc. now owns 81,395 shares of the company’s stock worth $924,000 after purchasing an additional 59,081 shares during the period. Finally, Vanguard Group Inc. lifted its position in shares of Stoke Therapeutics by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock worth $74,351,000 after purchasing an additional 217,616 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.